Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae
Meropenem/vaborbactam (Vabomere, VAY-boh-meer) will be the first antibiotic to combine a carbapenem with a beta-lactamase inhibitor.
Adding the beta-lactamase inhibitor vaborbactam helps meropenem outsmart carbapenem-resistant superbugs, which cause about 9,000 infections in the U.S. each year.
Meropenem/vaborbactam is approved to treat complicated urinary tract infections (UTIs), including pyelonephritis. Early evidence suggests it's also effective for bacteremia, pneumonia, and intra-abdominal infections.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals